Kaleido Biosciences’ (NASDAQ:KLDO) lock-up period will expire on Tuesday, August 27th. Kaleido Biosciences had issued 5,000,000 shares in its initial public offering on February 28th. The total size of the offering was $75,000,000 based on an initial share price of $15.00. After the expiration of Kaleido Biosciences’ lock-up period, company insiders and major shareholders will be able to sell their shares of the company.
Separately, Zacks Investment Research cut shares of Kaleido Biosciences from a “hold” rating to a “sell” rating in a research note on Tuesday, August 20th. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $17.70.
Shares of NASDAQ:KLDO opened at $9.01 on Monday. Kaleido Biosciences has a 52 week low of $6.23 and a 52 week high of $19.00. The business has a fifty day simple moving average of $8.36.
Hedge funds have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC purchased a new position in shares of Kaleido Biosciences during the 2nd quarter worth about $56,000. Northern Trust Corp purchased a new stake in Kaleido Biosciences in the 2nd quarter valued at about $145,000. Menta Capital LLC purchased a new stake in Kaleido Biosciences in the 2nd quarter valued at about $164,000. Charles Schwab Investment Management Inc. purchased a new stake in Kaleido Biosciences in the 2nd quarter valued at about $353,000. Finally, Dean Capital Investments Management LLC purchased a new stake in Kaleido Biosciences in the 1st quarter valued at about $611,000. 78.74% of the stock is owned by hedge funds and other institutional investors.
Kaleido Biosciences Company Profile
Kaleido BioSciences, Inc develops microbiome metabolic therapies. It offers treatment for hyperammonemia, a metabolic condition generally characterized by elevated levels of ammonia in the blood; infections caused by multi-drug resistant bacteria; chronic kidney disease; atherosclerotic cardiovascular disease; and drug or disease induced diarrhea.
Read More: Buy-Side Analysts
Receive News & Ratings for Kaleido Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kaleido Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.